The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications - Duan, Xiangling; Zhang, Xiaomeng; Sun, Bao (Cardiovascular diabetology, 2025)
Keywords: Animals; Antidiabetics; Biomarkers; Blood Glucose - drug effects; Blood Glucose - metabolism; Cardiac function; Cardiovascular system; Congestive heart failure; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diabetes Mellitus, Type 2 - physiopathology; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; DPP4i; Drugs; Ejection fraction; Epidemiology; Fatty acids; GLP-1 RA; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor Agonists; Heart failure; Heart Failure - diagnosis; Heart Failure - drug therapy; Heart Failure - epidemiology; Heart Failure - physiopathology; HFpEF; Hospitalization; Humans; Hyperglycemia; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Incretins - adverse effects; Incretins - therapeutic use; Males; Metabolism; Mortality; Oxidative stress; Pathophysiology; Peptides; Review; Risk Factors; SGLT2i; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Stroke Volume - drug effects; T2DM; Treatment Outcome; Ventricular Function, Left - drug effects; United States--US; GLP-1 RA; T2DM; DPP4i; HFpEF; SGLT2i